Kyverna Therapeutics Inc (KYTX) 13F Ownership Report (Q2 2026)

Kyverna Therapeutics (KYTX) issued a press release on August 11, 2026, with a business update and financial results for the quarter ended June 30, 2026. The 8-K reports this under Item 2.02 and includes the release as Exhibit 99.1, with Item 9.01 covering the exhibit. The excerpt doesn't include any revenue or loss figures, so this filing alone doesn't tell us whether results were strong or weak.

Kyverna Therapeutics (KYTX) has signed a new Clinical and Commercial Supply Agreement with ElevateBio Basecamp, replacing their earlier manufacturing deal. The agreement covers development and production of Kyverna's lead drug miv-cel, and includes minimum purchase commitments that kick in after regulatory approval, such as from the FDA. The contract runs for five years with automatic renewals, and prices can be adjusted annually based on inflation. Key commercial terms will be disclosed later in a confidential SEC filing.

Kyverna Therapeutics (KYTX) amended its loan agreement with Oxford Finance on July 8, 2026, effective June 30, 2026. The amendment extends the draw deadline for the remaining $15 million of Term A loans from June 30, 2026 to December 31, 2026, in exchange for a $187,500 fee. If Kyverna draws the full $15 million, the amendment also revises the terms for additional borrowings—a $5–20 million Term B loan and two $20 million Term C loans—each tied to achieving clinical or revenue milestones, and introduces minimum revenue covenants starting in the quarter ending June 30, 2027, September 30, 2027, or December 31, 2027, depending on other capital sources.